Compare OFRM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFRM | MNPR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.3M | 587.4M |
| IPO Year | 2025 | 2019 |
| Metric | OFRM | MNPR |
|---|---|---|
| Price | $17.13 | $107.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $27.75 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 441.3K | 266.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.42 | N/A |
| Revenue Next Year | $34.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $29.18 |
| 52 Week High | $27.00 | $124.82 |
| Indicator | OFRM | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 47.33 |
| Support Level | $14.42 | $102.88 |
| Resistance Level | $17.17 | $114.60 |
| Average True Range (ATR) | 1.09 | 6.71 |
| MACD | 0.07 | -1.60 |
| Stochastic Oscillator | 55.56 | 12.57 |
Once Upon a Farm PBC is a provider of baby food products. The company provides childhood nutrition with real, organic, farm-fresh food-made with no added sugar, no preservatives, and nothing artificial. Its products are available at retail customers, including Target, Whole Foods, Kroger, Walmart, Publix, and Wegmans. Its key products include Smoothies, Yogurt, Milk Shakes, Oat Bars, etc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.